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Abstract
Background:  The human CD44 gene contains 10 variable exons (v1 to v10) that can be
alternatively spliced to generate hundreds of different CD44 protein isoforms. Human CD44
variable exon v3 inclusion in the final mRNA depends on a multisite bipartite splicing enhancer
located within the exon itself, which we have recently described, and provides the protein domain
responsible for growth factor binding to CD44.
Findings: We have analyzed the sequence of CD44v3 in 95 mammalian species to report high
conservation levels for both its splicing regulatory elements (the 3' splice site and the exonic
splicing enhancer), and the functional glycosaminglycan binding site coded by v3. We also report
the functional expression of CD44v3 isoforms in peripheral blood cells of different mammalian taxa
with both consensus and variant v3 sequences.
Conclusion: CD44v3 mammalian sequences maintain all functional splicing regulatory elements as
well as the GAG binding site with the same relative positions and sequence identity previously
described during alternative splicing of human CD44. The sequence within the GAG attachment
site, which in turn contains the Y motif of the exonic splicing enhancer, is more conserved relative
to the rest of exon. Amplification of CD44v3 sequence from mammalian species but not from birds,
fish or reptiles, may lead to classify CD44v3 as an exclusive mammalian gene trait.
Background
The CD44 family of transmembrane glycoproteins medi-
ates the response of cells to their extracellular microenvi-
ronment by regulating growth, survival, differentiation
and motility. All human CD44 proteins are encoded by a
single, highly conserved gene containing 20 exons, 12 of
each undergo alternative splicing [1] (see figure 1A).
Complex alternative splicing of the central region of the
gene is responsible for the incorporation of the variable
domains to shape, predominantly, the extracellular,
membrane-proximal stem structure of the protein. The
heterogeneity of the CD44 protein products can be further
increased by post-translational modifications [1-4]. The
sequence encoded in exon v3 contains an optimal Ser-
Gly-Ser-Gly (SGSG) consensus motif for modification by
heparan sulfate (HS) side chains, to which several
heparin-binding proteins attach [5]. This unique HS addi-
tion site is critical for CD44v3 isoforms' capacity to bind
and present HS-dependent growth factors.
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Human variable exon v3 can follow a specific alternative
splicing route different from that affecting other variable
exons so it can be included in the mRNA together with
other variable exons or independently from them [6,7].
This inclusion is regulated by a multisite bipartite exonic
splicing enhancer (ESE) consisting in a tandem nonamer
(XX motif) and a heptamer (Y motif) that act coopera-
tively for the efficient recognition of the splice sites [8].
The XX motif is located centrally in the exon while the Y
motif is located within the sequence coding for the gly-
cosaminglycan (GAG) binding site immediately down-
stream from the SGSG motif in v3 (figure 1B).
In order to address the existence and functional nature of
the XXY ESE in non-human species we have evaluated the
overall level of conservation of CD44 exon v3, including
its splicing regulatory elements-the 3' splice site (3'ss), the
XXY splicing enhancer- and the GAG binding site, in 95
mammalian species. We also provide data of CD44v3
inclusion into mRNA from peripheral blood samples, by
means of RT-PCR, in some representative mammalian
taxa with differing levels of conservation of the sequence
elements analyzed.
Methods
Frozen (-80°C) blood samples were selected from the ani-
mal tissue bank of the Department of R+D+I, Laboratorio
Dr. Echevarne, Barcelona, Spain. Genomic DNA was iso-
lated from 200 μl of blood using the NucleoSpin Blood kit
(Macherey-Nagel) following manufacturer's instructions.
PCR amplification of CD44v3 was performed with
INT6SF and I7wtR primer set or -49v3F and I7wtR primer
set (table 1) using PCR Master Mix (Promega). PCR bands
of interest were isolated from agarose using the NucleoS-
pin Extract II kit (Machery-Nagel), sequenced in both
directions with the primers used during PCR and the CEQ
Dye Terminator Cycle Sequencing Quick Start kit (Beck-
man Coulter) and analyzed in a CEQ 8800 Genetic Anal-
CD44 exon v3 Figure 1
CD44 exon v3. A) Genomic structure of human CD44 gene (gray boxes, constitutive exons; white boxes, alternative exons; 
black box, variable exon v3; black line, introns). B) Schematic representation of exon v3 and its flanking introns (gray boxes, 
relative location of the XX and Y splicing enhancer motifs; white box, relative location of the nucleotides coding for the GAG 
binding site and the SGSG motif). Genomic DNA amplification was performed with PCR primers located in intron 6 and in the 
v3-intron 7 junction (indicated by arrows).
v3
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Table 1: Primers
Primer Region Sequence
INT6SF Intron 6 5'-ACCTTCTGTGCCTGATTTTC-3'
I7wtR Exon v3-intron 7 5'-AATTGATTATTCTTACTGGTGCTGG-3'
-49v3F Intron 6 5'-GCTTGGCGTCCAGCTCAG-3'
E20F-VI Exon 20 5'-GGGCAGAAGAAAAAGCTAGTNAT-3'
E20R-QEM Exon 20 5'-CCAAATGCACCATYTCYTG-3'
13v3F Exon v3 5'-ATATCATCTCAGCAGGCT-3'
100v3R Exon v3 5'-TCATCAATGCCTGATCCA-3'BMC Research Notes 2008, 1:57 http://www.biomedcentral.com/1756-0500/1/57
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ysis System (Beckman Coulter). All sequences were edited
to remove ambiguous base calls and primer sequences
and submitted to GenBank.
CD44 RT-PCR was performed from total RNA extracted
from frozen blood samples with a modification of the
QIAamp RNA Blood Mini kit protocol (QIAGEN). Briefly,
150 μl of frozen blood were lysed at 70°C for 10 min with
RLT/β-mercaptoethanol buffer containing 4 mg/ml Pro-
teinase K and centrifuged at 10,000 × g for 3 min. 450 μl
of the lysate supernatant were mixed with 225 μl of abso-
lute ethanol and loaded in a QIAamp spin column follow-
ing manufacturer's instructions. Eluted RNA was treated
with RQ1 RNase-free DNase (Promega) at 37°C for 30
min and purified following the QIAamp RNA Mini proto-
col for RNA cleanup (QIAGEN). The first-strand reaction
was performed with random primers (Promega) and
SuperScript II Reverse Transcriptase (Invitrogen). As con-
trol of RNA quality, total CD44 isoforms were amplified
with degenerate E20F-VI and E20R-QEM primer set (table
1) using GC-Rich PCR System (Roche).
In order to amplify CD44v3 containing isoforms, PCR
primers were designed based on a multiple sequence
alignment containing the sequences corresponding to the
95 mammalian species. Exon v3 positions that showed
full conservation were identified and selected to locate the
3' ends of the primers ensuring perfect matches. According
to this, v3 amplification was perfomed with primers
13v3F and 100v3R (table 1) and PCR Master Mix
(Promega). As control of complete genomic DNA diges-
tion, non reverse-transcribed RNAs were tested amplifica-
tion negative with primers 13v3F and 100v3R.
Molecular conservation analyses were conducted using
the MEGA version 3.1 software [9] and sequence logos
were generated with the WebLogo application [10].
Results
CD44v3 sequencing
There is little sequence data available for CD44 variable
exons from most animal species. The orthologue predic-
tion for human CD44 in Ensembl release 48 provides v3
exon sequence for 16 species of mammals. In order to
increase the data available we studied CD44 exon v3 in
most of the animal samples stored in our tissue bank.
A region that enabled amplification of CD44v3, was
located by a Blast search against multiple species using a
human genomic fragment spanning intron6-v3-intron7.
Alignment of sequences corresponding to the 10 nt at the
3' end of the INT6SF primer matched perfectly in Macaca
mulatta, Canis familiaris, Oryctolagus cuniculus and Pan trog-
lodytes and presented a single nucleotide missmatch in
Mus musculus, Rattus norvegicus, Loxodonta africana and Bos
taurus. Likewise, primer I7wtR matched perfectly with the
exception of Mus musculus where there was a single nucle-
otide missmatch. We tested primers INT6SF and I7wtR in
Loxodonta africana, Canis familiaris, Bos taurus, Oryctolagus
cuniculus and in non-mammalian species such as Sphenis-
cus humboldti,  Psittacus erithacus and  Varanus niloticus.
Sequence confirmation of PCR products showed that only
mammalian species amplified CD44v3. We failed to
amplify v3 (exonic and/or flanking intronic sequences)
from Spheniscus humboldti, Psittacus erithacus, Cygnus atra-
tus,  Threskiornis aethiopicus,  Dacelo novaguineae,  Ciconia
ciconia, Amazona aestiva, Guaruba guarouba, Varanus niloti-
cus,  Sparus aurata,  Merluccious merlucius and  Plesionika
edwarsii. In the absence of v3 specific PCR amplification
we cannot evaluate the presence/absence of v3 nor the
lack of conservation of primer regions. Lack of v3 amplifi-
cation from bird, fish or reptile DNA is in agreement with
the absence of exon v3 from available genomes of Gallus
gallus  [GenBank: NC_006092],  Xenopus tropicalis
[Ensembl: ENSXETG00000007556] and Gasterosteus
aculeatus [Ensembl: ENSGACG00000011430].
In view of this, our sample set has been restricted to 95
mammalian species distributed in 29 families. The region
amplified comprises, relative to the known human
CD44v3 sequence, a 5' partial fragment of intron 6 and a
3' partial fragment of exon v3 (117 nucleotides out of
126) (see figure 1B). The resulting sequences are shown in
Additional file 1.
CD44v3 splicing regulatory elements conservation
We have compared sequences of 140 nucleotides long
spanning 23 nucleotides of intron 6 and 117 nucleotides
of exon v3, in the mammalian species listed in Additional
file 1. The genomic region amplified enables the analysis
of the CD44v3 splicing regulatory elements, namely, the
3'ss and the XXY ESE [8]. The level of conservation at each
position of the alignment in the 95 species analyzed is
shown in figure 2A. Sequence alignment of exon v3 in
these species reveals 69 (59%) conserved and 48 (41%)
variable residues. In this way, the 95 species studied are
represented by 28 different nucleotide sequences.
The 3'ss is fully conserved in 84 out of 95 species. The rest
of species (11 out of 95) have single-nucleotide substitu-
tions at positions -5 (n = 1), -6 (n = 2), -7 (n = 6) or -8 (n
= 2) (see figure 2B). The functional significance of these
varying positions in the splice site is addressed below by
means of v3 expression analysis in peripheral blood.
The percentage of conserved residues in the ESE and in
exon v3 is 68% and 59%, respectively. These values sug-
gest that the level of conservation of the ESE with respect
to the exon is of the same range (figure 2A). Upon ESE dis-
section, XX reveals higher variability relative to Y (figureBMC Research Notes 2008, 1:57 http://www.biomedcentral.com/1756-0500/1/57
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Nucleotide sequence conservation Figure 2
Nucleotide sequence conservation. A) Top, line plot displaying the level of conservation at each position of the alignment 
of the 95 species analyzed (dark gray boxes, location of 3'ss, XX and Y splicing enhancer motifs; light gray box, GAG binding 
site). Bottom, schematic representation of the genomic region aligned. B) Sequence logo of the 3'ss. Positions are numbered 
according to the exon sequence. C) Sequence logo of the XX and Y splicing enhancer motifs. Positions are numbered accord-
ing to the exon sequence.
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2A and 2C) which remains conserved in all species with
the exception of Elephas maximus, Loxodonta africana and
Ursus arctos which present synonymous variations (see
Additional file 1). If we consider the XXY ESE as a whole
unit of 25 nucleotides long, such unit is represented by 13
different sequences whose relative frequency is shown in
table 2. The most common sequence is # 10, present in
42% of the species tested and followed by # 2, present in
28% of the species. The latter corresponds to the previ-
ously described human sequence [8] and it is also
detected in other primate families. The third most com-
mon sequence is # 8, present in 11% of the species. The
analysis of the XXY sequences reveals 17 (68%) conserved
and 8 (32%) variable residues of which most are single-
nucleotide substitutions. Within the XX motif, positions 3
(conserved in 58 sequences out of 95), 4 (92 out of 95)
and 10 (88 out of 95) are represented by 3 different nucle-
otides. The positions that have been functionally shown
elsewhere to decrease CD44v3 inclusion in mutant
expression constructs (X mutant: AAATGggtA and Y
mutant: ATGggtA) [8] remain invariant, corroborating
their functional importance during splicing.
CD44v3 GAG binding site conservation
Considering v3's reading frame (codon start = 3), the 117
nucleotides of CD44 exon v3 translate into a 38 amino
acid extracellular protein domain. Amino acid sequence
alignment of this domain from our data set shows 12
(32%) conserved and 26 (68%) variable residues classify-
ing the 95 species studied into 28 different amino acid
sequence groups. This alignment also reveals full conser-
vation of the SGSG motif (figure 3A) with the exception of
Tursiops truncatus and  Oryctolagus cuniculus where the
sequences have been changed to SGSD and PGSG, respec-
tively (see Additional file 1). Bourdon et al [11] identified
the amino acid sequence homology around the SG dipep-
tide sites that serves as GAG attachment sites in the core
proteins of proteoglycans. The core protein must contain
acidic amino acids on the amino-terminal side of the
sequence SGXG, where X stands for any amino acid. The S
is the most critical of the invariant residues and the rela-
tive importance of the residues is S > first G > second G >
acidic residues. According to this, only the rabbit's v3
domain would not be expected to bind HS.
Human exon v3 contains acidic residues both upstream
and downstream of the SGSG motif. The eight amino
acids located downstream of the SGSG site consist of
acidic residues flanked by hydrophobic residues that are
necessary for the specific addition of HS at this site [12].
The species analyzed maintain a conserved GAG binding
site both at the nucleotide (see figure 2A) and the amino
acid level (figure 3B) implying that the secondary and/or
tertiary structure around the SGSG motif is critical to ini-
tiate HS attachment, and this may have further contrib-
uted to the conservation of the Y ESE motif contained
therein in all species tested.
CD44v3 expression in mammalian species
CD44v3 has been reported to be constitutively expressed
in human peripheral blood cells, irrespective of their acti-
vation status [13-15]. We have used peripheral blood
accordingly as a model to evaluate the expression of
CD44v3 isoforms in some taxon-representative mamma-
lian species. The RT-PCR results (see Additional files 1 and
2) show that there is no correlation between sequence var-
iation within the 3'ss or the ESE and lack of v3 expression
in peripheral blood. All species tested have revealed v3
expression implying that the conservation observed is suf-
ficient to maintain v3 inclusion. The human CD44 pro-
tein contains an unique HS binding site coded by CD44
exon v3 [16], therefore enabling only CD44v3 containing
Table 2: Sequences representing the XXY ESE in CD44v3
XXY ID Sequence (XX_Y) N Species freq (%) N changes*
1 AAaTGAAGAAAAcGAAGA_ATGAAGA 2 2.11 2
2 AAaTGAAGAAAATGAAGA_ATGAAGA 27 28.42 1
3 AAaTGAAGAAAATGAAGA_ATGAgGA 2 2.11 2
4 AAaTGAAGAcAATGAAGA_ATGAAGA 3 3.16 2
5 AAaTGAgGAAAATGAAGA_ATGAAGA 1 1.05 2
6 AACaGAAGAAAAcGAAGA_ATGAAGA 2 2.11 2
7 AACcGAAGAAAAcGAAGA_ATGAAGA 1 1.05 2
8 AACTGAAGAAAAcGAAGA_ATGAAGA 11 11.58 1
9 AACTGAAGAAAATGAAGA_AcGAAGA 1 1.05 1
10 AACTGAAGAAAATGAAGA_ATGAAGA 40 42.11 0
11 AACTGAAGAcAATGAAGA_ATGAAGA 3 3.16 1
12 cAgTGAAGAAAATGAAGA_ATGAAGA 1 1.05 2
13 cAgTGAAGAtAAcGAAGA_ATGAAGA 1 1.05 4
Each XXY sequence is represented by an identification number (XXY ID). Variable positions relative to most common sequence (#10) are 
indicated in lower case. Number of species representing each sequence and its relative frequency are displayed.
*Total number of changes relative to #10.BMC Research Notes 2008, 1:57 http://www.biomedcentral.com/1756-0500/1/57
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Amino acid sequence conservation Figure 3
Amino acid sequence conservation. A) Line plot displaying the level of conservation at each position of the alignment of 
the 95 species analyzed (dark gray box, location of SGSG motif; light gray box, GAG binding site). B) Sequence logo of the 
GAG binding site. Positions are numbered according to the v3 coded domain.
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isoforms to carry HS side chains and to bind and present
heparin-binding growth factors and cytokines. On this
basis, presence of a conserved GAG attachment site in all
mammals studied may reflect a similar function [17,18]
for CD44v3 in these species.
In addition to mammals, CD44 constitutive exons are
also found in birds, amphibians and fish as described in
public databases although their expression in certain tis-
sues in such taxa has not been addressed. In conclusion,
we have obtained CD44v3 sequence from 95 mammalian
species but have failed to amplify the homologous frag-
ment from bird, reptile or fish species, in agreement with
the lack of CD44 variable exons from available genome
sequences of model organisms in these taxa. This implies
that CD44v3 appears to be an exclusive mammalian gene
trait. The sequence conservation observed in our dataset
would support a common origin and function for this
exon in all mammals. Furthermore, CD44v3 sequence
conservation in mammalian species enables maintenance
of functional splicing regulatory elements and the GAG
binding site. The level of conservation of the sequence
encoding the GAG binding site, which in turn contains
the Y motif of the ESE analysed, is higher than the overall
level found for the rest of the exon. Whether this phenom-
enon is due to purifying selection pressure contributed by
the GAG attachment domain alone or in conjunction with
the Y motif of the ESE remains undetermined. Functional
inclusion of CD44v3 has also been demonstrated in
peripheral blood from mammalian species representative
of the different sequence variations observed, implying in
vivo  use of exon v3 in these species. Further work is
required to search for the exact evolutionary origin of
CD44 exon v3 in mammals.
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